GlassScriptPhysician profile
Jennifer Blyler
NPI 1841073392
$1,089.88
in general payments reported to CMS, 2019-2025
15 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $235 · 2024: $499 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $990 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $989.93 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $153.00 | 2023-2024 | Imfinzi |
| Merck Sharp & Dohme LLC | $143.67 | 2024-2025 | Keytruda, Verquvo |
| Scpharmaceuticals INC. | $126.18 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $106.33 | 2023 | Opsumit, Uptravi |
| Astellas Pharma US INC | $99.95 | 2023 | |
| Tactile Systems Technology INC | $83.00 | 2024 | Entre Plus, Flexitouch Plus |
| Amgen INC. | $78.97 | 2025 | Repatha |
| Novo Nordisk INC | $73.39 | 2025 | Ozempic, Wegovy |
| Pfizer INC. | $56.85 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.63 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $33.59 | 2024 | |
| Heartflow, INC. | $33.15 | 2025 | |
| Eisai INC. | $20.18 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.90 | 2025 | |
| Adc Therapeutics America, INC. | $13.09 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Blyler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.